Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Time to first relapse as an endpoint in multiple sclerosis clinical trials.
Neurodegenerative diseases and therapeutic strategies using iron chelators.
Disability progression in relapsing MS is more than just lesions: The lesson of fingolimod.
[Microglia in pathophysiology of neuroimmunological disorders].
Living with multiple sclerosis.
Neuregulin and BDNF Induce a Switch to NMDA Receptor-Dependent Myelination by Oligodendrocytes.
Transplantation of olfactory ensheathing cells promotes partial recovery in rats with experimental autoimmune encephalomyelitis.
The Evidence for a Beneficial Role of Vitamin A in Multiple Sclerosis.
Exosomes in neurologic and psychiatric disorders.
Stereotactic neurosurgery for disabling tremor in multiple sclerosis: thalamotomy or deep brain stimulation?
Treatment of Neuromyelitis Optica: Review and Recommendations.
Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases.
Early netrin-1 expression impairs central nervous system remyelination.
[Uveitis in multiple sclerosis : Overview and perspectives.]
Affinity Proteomic Profiling of Plasma, Cerebrospinal Fluid, and Brain Tissue within Multiple Sclerosis.
Glial progenitor cell-based treatment and modeling of neurological disease.
The diagnostic and prognostic value of neurofilament heavy chain levels in immune-mediated optic neuropathies.
Activated Invariant NKT Cells Control Central Nervous System Autoimmunity in a Mechanism That Involves Myeloid-Derived Suppressor Cells.
Gait variability and multiple sclerosis.
A nexus between lipids and multiple sclerosis?
Extracellular matrix metalloproteinase inducer shows active perivascular cuffs in multiple sclerosis.
The cooling effect on proinflammatory cytokines interferon-gamma, tumor necrosis factor-alpha, and nitric oxide in patients with multiple sclerosis.
Clinically isolated syndromes suggestive of multiple sclerosis: an optical coherence tomography study.
The risks for falls and fractures in multiple sclerosis.
Astrocyte TNFR2 is required for CXCL12-mediated regulation of oligodendrocyte progenitor proliferation and differentiation within the adult CNS.
Pages
« first
‹ previous
…
348
349
350
351
352
353
354
355
356
…
next ›
last »